ArticleScientific reports2026
Clinical outcomes of the new generation VISUMAX 800 platform in small incision lenticule extraction for Myopia in Chinese patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective multicentre study assessed early refractive outcomes and safety of small incision lenticule extraction (SMILE) in Chinese myopic eyes and characterised astigmatic accuracy and higher-order aberration (HOA) changes. Adults who underwent SMILE using new generation VISUMAX 800 with CentraLign centration and OcuLign iris registration participated. The participants comprised 319 patients (605 eyes) (mean age 20.6 ± 4.1 years; mean preoperative spherical equivalent [SE], - 3.88 ± 1.50 dioptres [D]). At 6 months, the mean uncorrected distance visual acuity was - 0.10 ± 0.05 logarithm of the minimum angle of resolution and mean manifest refractive SE was + 0.25 ± 0.33 D; 83.0% and 100.0% of eyes were within ± 0.50 D and ± 1.00 D of target SE, respectively. Residual cylinder was ≤ 0.50 D in 97.5% and ≤ 1.00 D in 100.0%. The Alpins analysis suggested mild undercorrection (correction index, 0.94 ± 0.23; difference vector, 0.21 ± 0.18 D). HOA root mean square increased (0.42 ± 0.03 to 0.57 ± 0.10 μm; P < 0.01), whereas spherical aberration was unchanged (P = 0.55). Decentration-coma analyses showed no significant associations between signed or total decentration parameters and corresponding coma changes after false discovery rate adjustment. Complications were infrequent. SMILE with VISUMAX 800 showed favourable early visual recovery, high predictability, low residual astigmatism, and acceptable safety profile in a multicentre real-world cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.